Precise. Effective. Safe.

The Problem

Mucus plugs are a core problem in COPD

COPD affects an estimated 400 million people worldwide and is a leading cause of death globally. Mucus plugging is common in COPD and has been reported in a substantial proportion of patients, where it is associated with airflow obstruction, disease severity, and adverse clinical outcomes. Current approved COPD therapies are not specifically designed to remove or directly target mucus plugs, highlighting an important unmet need in patient care.

At MucoLife Therapeutics we have a solution to the problem.

Our Solution is Precise

MLT-001 is a modern first-in-class mucus modulator

MLT-001 is MucoLife’s lead investigational inahed therapy designed to dissolve mucus plugs obstructing the airways. It is an oligomer of naturally occurring amino acids that effectively capture and remove calcium ions that mediate mucus stabilization and aggregation in the lungs. MLT-001 is a patented, first-in-class therapeutic approach with the potential to deliver meaningful benefits to patients.
In preclinical development. Not yet approved by any regulatory authority.

Four laboratory glassware items filled with colorful liquids: a tall test tube with blue liquid, a small test tube with green liquid, and two Erlenmeyer flasks filled with red and green liquids, arranged on a white background.

Our Solution is Effective

MLT-001 has a unique mechanism of action that allows effective clearance of the airways

Unlike current medications, MLT-001 targets the root cause of COPD by detaching excess mucus, with potential to significantly improve airflow and slow or halt disease progression.

In COPD patients, persistent mucus plugging leads to a decline in lung function, decreased quality of life, and a heightened risk of all-cause mortality. MLT-001 is designed to reverse disease progression by eliminating mucus plugs. It shows preclinical promise as a valuable addition to the treatment landscape for COPD, with potential expansion into other mucus-related lung diseases such as asthma, bronchiectasis, and cystic fibrosis.

An elderly man and woman are smiling and sharing a moment on a swing set during autumn. The woman, wearing glasses and a red scarf, is seated on the swing, while the man, wearing a green cap, glasses, and a blue jacket, is standing nearby, holding the swing's chain and looking at her.

Our Solution is Safe

MLT-001 offers a unique advantage by directly and locally targeting airway mucus plugs

MLT-001 does not act on airway cells hidden beneath the mucus, making it an ideal candidate for inhaled therapy. MLT-001 acts locally in the airways, minimizing the risk of unwanted side effects from systemic medications affecting the entire body. By targeting a key mechanism underlying mucus obstruction, MLT-001 has the potential to address an important driver of muco-obstructive lung disease, rather than solely alleviating symptoms.